Systemic lidocaine and human somatosensory-evoked potentials during sufentanil-isoflurane anaesthesia.
The effect of systemically administered lidocaine on somatosensory evoked potentials (SSEPs) during general anaesthesia has not been widely reported. Knowledge of the influence of anaesthetic agents on evoked potentials assists in interpreting evoked potential waveforms. Accordingly, we studied the behaviour of cortical and subcortical (recorded at the second cervical vertebra) SSEPs after administration of intravenous lidocaine (3 mg.kg-1 bolus followed by infusion at 4 mg.kg-1.hr-1) during a sufentanil-based anaesthetic regimen in 16 patients undergoing abdominal or orthopaedic surgery. When compared to awake baseline recordings, the sufentanil-nitrous oxide, low-dose isoflurane anaesthetic depressed N1 amplitude by approximately 40% and prolonged latency by 10%. Fifteen minutes after establishment of this anaesthetic, the amplitude and latency of N1 were 1.13 +/- 0.56 microV and 19.81 +/- 1.63 msec, respectively. Within five minutes of adding lidocaine, amplitude decreased further to 0.84 +/- 0.39 microV (P = 0.001), while latency was extended to 20.44 +/- 1.48 msec (P = 0.01). Lidocaine did not affect cervical amplitude and prolonged latency only minimally. Despite the observed effects on amplitude and latency, SSEP waveforms were preserved and interpretable. Plasma lidocaine levels obtained at 5, 20, and 40 minutes after lidocaine were 5.17 +/- 1.33, 3.76 +/- 1.14, and 3.66 +/- 0.9 micrograms.dl-1, respectively. Our results indicate that systemically administered lidocaine at therapeutic plasma levels acts synergistically with a sufentanil-based anaesthetic to depress the amplitude and prolong the latency of SSEPs.
Schubert
A
A
Division of Anesthesiology, Cleveland Clinic Foundation, Ohio 44195-5154.
Licina
M G
MG
Glaze
G M
GM
Paranandi
L
L
D000328:Adult; D000769:Anesthesia, Inhalation; D000771:Anesthesia, Intravenous; D000777:Anesthetics / Q000494:pharmacology; D001794:Blood Pressure; D002245:Carbon Dioxide / Q000378:metabolism; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects*; D005283:Fentanyl / Q000031:analogs & derivatives* / Q000494:pharmacology; D006339:Heart Rate; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007530:Isoflurane / Q000378:metabolism / Q000494:pharmacology; D008012:Lidocaine / Q000008:administration & dosage / Q000494:pharmacology*; D008475:Median Nerve / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011930:Reaction Time / Q000187:drug effects; D017409:Sufentanil; D013990:Tidal Volume
D000777:Anesthetics; D002245:Carbon Dioxide; D008012:Lidocaine; D017409:Sufentanil; D007530:Isoflurane; D005283:Fentanyl